Leading Drug Fails to Slow Alzheimer’s Progression

By News Health
21 minutes Ago

(MedPage Today) — Alzheimer’s patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to…

Source link : https://www.medpagetoday.com/meetingcoverage/ctad/118850

Author :

Publish date : 2025-12-05 15:57:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Makary Claims Biden Team Hid COVID Vax Risks; Rabies via Transplant; 200K Kid Deaths

Real-World Data Support for Lecanemab in Early AD

Failed Semaglutide Trials for AD: Not the End of the Road?

Seven Digital Cardiac Rehab Tools Backed by NICE

Can 15-Channel Coil MRI Improve Bone Invasion Detection?

Quality of Life Varies With Advanced Ulcerative Colitis Care